Implementation of personalized medicine and pharmaco(epi)genetic biomarkers for improvement of lung cancer treatmentOngoing
Despite advances in pharmacology, not all lung cancer patients respond favourably to costly therapies. Genetic polymorphisms and epigenetic regulation of transporters, drug-metabolizing enzymes, DNA repair and proteins of cell cycle and apoptosis contribute in interindividual variation in therapy response in Cuban lung cancer patients. In this project, pharmaco(epi)genetic biomarkers will be developed for personalized medicinal health applications, allowing stratification of Cuban lung cancer patients that are more likely to benefit from a given cancer therapy or to prevent adverse reactions of unresponsive patients.
13/03/2016 - 30/04/2021